The Tajik Ministry of Health and Médecins Sans Frontières (MSF) began a comprehensive paediatric tuberculosis (TB) care programme in 2011. The paediatric TB project in Dushanbe aims to decrease the TB morbidity and mortality rates among children and their family members. In 2013, MSF documented this, producing a report about improving paediatric TB care.
Following the progress made in treating paediatric TB in Tajikistan, MSF produced a follow-up report titled Breaking the cycle: Paediatric DR-TB detection, care and treatment in Tajikistan. This new report documents the progress made during the last five years, and reflects on the sustainability of the programme and the challenges and opportunities that lie ahead.
Read, watch, shareBreaking the cycle: Paediatric DR-TB detection, care and treatment in Tajikistan > Paragraphs
In an effort to make lifesaving drugs accessible to all people, civil society organisations around the world have worked tirelessly to remove patent barriers on drugs for the treatment of cancer, HIV and hepatitis C. In India, the largest manufacturer of affordable drugs for the developing world, the struggle to scale up access to medicines for drug-resistant tuberculosis (DR-TB) is now at a decisive stage. Médecins Sans Frontières (MSF) and civil society organisations in the country are supporting a patent challenge filed by two TB survivors in order to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the core DR-TB drug bedaquiline.